Media

Conducted in two stages, the Phase 1 clinical trial will examine the safety and tolerability of the reformulated bisantrene, RC220, in particular the drug’s cardioprotective ability when used in combination with doxorubicin, a form of anthracycline commonly used in chemotherapy. The ethics submission is a milestone after a year’s preparation, with the first patient recruitment…

Race Oncology Ltd (ASX:RAC, OTC:RAONF) has taken another key step toward a Phase 1 trial in solid tumour patients using RC220 bisantrene by submitting an application for an ethics and regulatory package to Bellberry Human Research Ethics Committee (HREC) for approval. Read the full article here. Watch the interview with CEO and MD Dr Daniel Tillett.

Race CEO Dr Daniel Tillett joins Proactive’s Tylah Tully to discuss the FTO drug discovery program the company has concluded at Monash University’s Fragment Platform (MFP). Watch the full interview below and for the full news report via this link.

CEO and MD Dr Daniel Tillett joined ausbiz post the release of September Quarterly Activity Report, reaffirming the company’s strong funding position, clinical pipeline, and noting changes in the Board and Management team. Watch the full interview via this link.

Race Oncology joins four other biotech companies to present at HealthInvest 2024, hosted by IR Department, Morgans and Stockhead. At the conference, Race presented the clinical development history of its lead asset bisantrene, and the pipeline for the coming months to investors, analysts and industry peers in the room. Watch the interview with Dr Peter…

Race Executive Chair Dr Peter Smith speaks with Proactive about the recent board changes and the company’s clinical pipeline for its lead drug asset, bisantrene. Read the full report here.

Race Oncology is pleased to release the FY24 annual report. Key highlights include: Read the full report via this link.

Race is pleased to be featured in Stockhead’s Investor Guide this year. The Investor Guide showcases strong forces from the Australian health and biotech sector, offering deep insights to ASX investors. In this feature, Race CEO Dr Daniel Tillett shares the company’s journey of discovering and developing lead asset bisantrene, a unique drug for its…

Race CEO Dr Daniel Tillett speaks with Jonathan Jackson in the Proactive studio to discuss positive results from an investigator-sponsored Phase 1b/2 trial of RC110 bisantrene for acute myeloid leukaemia (AML). Read the article here, and watch the full interview below.